Neurological and Psychiatric Adverse Effects of Immunological Therapy (original) (raw)
Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. Cancer J Clin 1988; 38: 258–77 ArticleCAS Google Scholar
Fent K, Zbinden G. Toxicity of interferon and interleukin. Trends Pharmacol Res 1987; 8: 100–5 ArticleCAS Google Scholar
Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107: 293–300 PubMedCAS Google Scholar
Lenk H, Tanneberger S, Muller U, et al. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989; 24: 391–2 ArticlePubMedCAS Google Scholar
Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252: 938–41 ArticlePubMedCAS Google Scholar
Mattson K, Niiranen A, Iivanainen M, et al. Neurotoxicity of interferon. Cancer Treat Rep 1983; 67: 958–61 PubMedCAS Google Scholar
Meyers CA, Abbruzzese J. Cognitive functioning in cancer patients: effect of previous treatment. Neurology 1992; 42: 434–6 ArticlePubMedCAS Google Scholar
Waltrip RW, Carrigan DR, Carpenter WT. Immunopathology and viral reactivation. A general theory of schizophrenia. J Nerv Ment Dis 1990; 178: 729–38 ArticlePubMed Google Scholar
Preble O, Torrey E. Serum interferon in patients with psychosis. Am J Psychiatry 1985; 142: 1184–6 PubMedCAS Google Scholar
Piper BF, Rieger PT, Brophy L, et al. Recent advances in the management of biotherapy-related side effects: fatigue. Oncol Nurs Forum 1989; 16(4 Suppl.): 27–34 PubMedCAS Google Scholar
Smedley H, Katrak M, Sikora K, et al. Neurological effects of recombinant human interferon. BMJ 1983; 286: 262–4 ArticlePubMedCAS Google Scholar
Smith A, Tyrrell D, Coyle K, et al. Effects of interferon alpha on performance in man: a preliminary report. Psychopharmacology 1988; 96: 414–6 ArticlePubMedCAS Google Scholar
Iivanainen M, Laaksonen R, Niemi ML, et al. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 1985; 72: 475–80 ArticlePubMedCAS Google Scholar
McDonald E, Mann A, Thomas H. Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant interferon-alfa in hepatitis B carriers. Lancet 1987; 2: 1175–8 ArticlePubMedCAS Google Scholar
Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577–80 ArticlePubMedCAS Google Scholar
Meyers CA, Obbens EAMT, Scheibel RS, et al. Neurotoxicity of intraventricularly administered alpha interferon for leptomeningeal disease. Cancer 1991; 68: 88–92 ArticlePubMedCAS Google Scholar
Wadler S, Feel S, Haynes H, et al. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. Cancer 1993; 71: 1726–30 ArticlePubMedCAS Google Scholar
Rohatiner AZS, Prior PF, Burton AC, et al. Central nervous system toxicity of interferon. Br J Cancer 1983; 47: 419–22 ArticlePubMedCAS Google Scholar
Suter CC, Westmoreland BF, Sharbrough FW, et al. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 1984; 59: 847–50 PubMedCAS Google Scholar
Farkkila M, Iivanainen M, Roine R, et al. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis. Acta Neurol Scand 1984; 70: 42–6 ArticlePubMedCAS Google Scholar
Honigsberger L, Fielding JW, Priestman TJ. Neurologic effects of recombinant human interferon [letter]. BMJ 1983; 286: 719 ArticlePubMedCAS Google Scholar
Dantzer R, Bluthe RM, Kent S, et al. Behavioral effects of cytokines. In: Rothwell NJ, Dantzer RD, editors. Interleukin-L in the brain. New York: Pergamon Press, 1992: 135–50 Google Scholar
Triozzi PL, Kinney P, Rinehart JJ. Central nervous system toxicity of biological response modifiers. Ann NY Acad Sci 1990; 594: 347–54 ArticlePubMedCAS Google Scholar
Meyers CA, Mattis PJ, Pavol MA, et al. Pattern of neuro-behavioral deficits associated with interferon-a neurotoxicity [abstract]. Proc Am Assoc Cancer Res 1993; 34: 218 Google Scholar
Cummings JL, editor. Subcortical dementia. New York: Oxford University Press, 1990 Google Scholar
Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406–13 ArticlePubMedCAS Google Scholar
Bocci V. Central nervous system toxicity of interferons and other cytokines. J Biol Regul Homeost Agents 1988; 3: 107–18 Google Scholar
Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672–6 ArticlePubMedCAS Google Scholar
Liberati AM, Biscottini B, Fizzotti M, et al. A phase I study of human natural interferon-β in cancer patients. J Interferon 1989; 9: 339–48 ArticleCAS Google Scholar
The IFNB Multiple Sclerosis Study Group. Interferon beta-lb in effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1993; 43: 655–61 Google Scholar
von der Maase H, Geertsen P, Thatcher C, et al. Recombinant interleukin-2 in metastatic renal cell carcinoma - a European multicentre phase II study. Eur J Cancer 1991; 27: 1583–9 ArticlePubMed Google Scholar
Krigel R, Padavic-Shaller K, Rudolph A, et al. A phase I study of recombinant interleukin-2 plus recombinant beta interferon. Cancer Res 1988; 48: 3875–81 PubMedCAS Google Scholar
Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907–13 ArticlePubMedCAS Google Scholar
Meyers CA, Yung WKA. Delayed neurotoxicity of intraventricular interleukin-2: a case report. J Neurooncol 1993; 15: 265–7 ArticlePubMedCAS Google Scholar
Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 1988; 80: 1039–44 ArticlePubMedCAS Google Scholar
Meyers CA, Valentine AD, Wong FL, et al. Reversible neurotoxicity of IL-2 and TNF: correlation of SPECT with neuropsychological testing. J Neuropsychiatry Clin Neurosci 1994; 6: 285–8 PubMedCAS Google Scholar
Lipowski Z. Update on delirium. Psychiatr Clin North Am 1992; 15: 335–46 PubMedCAS Google Scholar
Slaby A, Erie S. Dementia and delirium. In: Stoudemire A, Fogel BS, editors. Psychiatric care of the medical patient. New York: Oxford University Press, 1993: 415–53 Google Scholar
Cummings JL, Benson FD. Dementia: a clinical approach. 2nd ed. Boston: Butterworth-Heinemann, 1992: 217–65 Google Scholar
Cohen-Cole S, Brown F, McDaniel JS. Assessment of depression and grief reactions in the medically ill. In: Stoudemire A, Fogel BS, editors. Psychiatric care of the medical patient. New York: Oxford University Press, 1993: 53–69 Google Scholar
Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry 1990; 71: 7 (Suppl.): 12–7 Google Scholar
Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6: 355–9 ArticlePubMedCAS Google Scholar
Ellison MD, Krieg RJ, Povlishock JT. Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions. J Neuroimmunol 1990; 28: 249–60 ArticlePubMedCAS Google Scholar
Saris SC, Rosenberg SA, Friedman RB, et al. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 1988; 69: 29–34 ArticlePubMedCAS Google Scholar
Ellison MD, Povlishock JT, Merchant RE. Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 1987; 47: 5765–70 PubMedCAS Google Scholar
Blatteis CM, Hales JRS, McKinley MH, et al. Role of the anteroventral third ventricle region in fever in sheep. Can J Physiol Pharmacol 1986; 65: 1255–60 Article Google Scholar
Shibata M, Blatteis C. Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum laminae terminalis. Brain Res 1991; 562: 323–6 ArticlePubMedCAS Google Scholar
Calvet M, Gresser I. Interferon enhances the excitability of cultured neurones. Nature 1979; 278: 558–60 ArticlePubMedCAS Google Scholar
Dafny N. Interferon modifies EEG and EEG-like activity recorded from sensory, motor, and limbic system structures in freely behaving rats. Neurotoxicology 1983; 4: 235–40 PubMedCAS Google Scholar
Dafny N, Prieto-Gomez B, Reyes-Vazquez C. Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity. J Neuroimmunol 1985; 9: 1–12 ArticlePubMedCAS Google Scholar
Prieto-Gomez B, Reyes-Vazquez C, Dafny N. Differential effects of interferon on ventromedial hypothalamus and dorsal hippocampus. J Neurosci Res 1983; 10: 273–8 ArticlePubMedCAS Google Scholar
Bindoni M, Perciavalle V, Berretta S, et al. Interleukin-2 modifies the bioelectric activity of some neurosecretory nuclei in the rat hypothalamus. Brain Res 1988; 462: 10–4 ArticlePubMedCAS Google Scholar
Berk M, Finkelstein J. Efferent connections of the lateral hypothalamic area of the rat: an autoradiographic investigation. Brain Res Bull 1982; 8: 511–26 ArticlePubMedCAS Google Scholar
Carpenter M, Sutin J. Human neuroanatomy. Baltimore: Williams & Wilkins, 1983 Google Scholar
Issacson R. The limbic system. New York: Plenum Press, 1982 Google Scholar
Villalobos J, Ferssiwi A. The differential ascending projections from the anterior, central, and posterior regions of the lateral hypothalamic area: an autoradiographic study. Neurosci Lett 1987; 81: 89–94 ArticlePubMedCAS Google Scholar
Villalobos J, Ferssiwi A. The differential descending projections from the anterior, central, and posterior regions of the lateral hypothalamic area: an autoradiographic study. Neurosci Lett 1987; 81: 95–9 ArticlePubMedCAS Google Scholar
Cotran RS, Pober JS, Gimbrone MA, et al. Endothelial activation during interleukin 2 immunotherapy: a possible mechanism for a vascular leak syndrome. J Immunol 1987; 137: 1883–8 Google Scholar
Saris SC, Patronas N, Rosenberg SA. The effect of intravenous interleukin-2 on brain water content. J Neurosurg 1989; 71: 169–74 ArticlePubMedCAS Google Scholar
Bernard JT, Ameriso S, Kempf RA, et al. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology 1990; 40: 154–5 ArticlePubMedCAS Google Scholar
Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989; 81: 497–502 ArticlePubMedCAS Google Scholar
Blalock JE, Smith EM. Human leukocyte interferon: structural and biological relatedness to adrenocorticotropic hormones and endorphins. Proc Nat Acad Sci USA 1980; 77: 5972–4 ArticlePubMedCAS Google Scholar
Blalock JE, Stanton JD. Common pathways of interferon and hormonal action. Nature 1980; 283: 406–8 ArticlePubMedCAS Google Scholar
Tracey K, Lowry S, Fahey T, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 1987; 164: 415–22 PubMedCAS Google Scholar
Tsagarakis S, Gillies G, Rees L, et al. Interleukin-1 directly stimulates the release of corticotropin releasing factor from rat hypothalamus. Neuroendocrinology 1989; 9: 98–101 Article Google Scholar
Schultzberg M. Location of interleukin-1 in the nervous system. In: Rothwell NJ, Dantzer RD, editors. Interleukin-1 in the brain. New York: Pergamon Press, 1992: 1–11 Google Scholar
Gottschall PE, Komaki G, Arimura A. Interleukin-1β activation of the central nervous system. In: Rothwell NJ, Dantzer RD, editors. Interleukin-1 in the brain. New York: Pergamon Press, 1992: 27–49 Google Scholar
McEwen B, Weis J, Schwartz L. Selective retention of corticosterone by limbic structures in rat brain. Nature 1968; 220: 911–2 ArticlePubMedCAS Google Scholar
McEwen B, De Kloet E, Rostene W. Adrenal steroid receptors and actions in the central nervous system. Physiological Rev 1986; 66: 1121–88 CAS Google Scholar
McEwen B, Micco D. Toward an understanding of the multiplicity of glucocorticoid actions on brain function and behavior. In: De Weid D, van Keep P, editors. Hormones and the brain. Baltimore, MD: University Park, 1980: 11–28 Chapter Google Scholar
Gray J. The neuropsychology of anxiety: an inquiry into the functions of the septo-hippocampal system. New York: Oxford University Press, 1982 Google Scholar
Lynch G. Synapses, circuits, and the beginnings of memory. Cambridge, MA: MIT Press, 1986 Google Scholar
Squire L. Memory and brain. New York: Oxford University Press, 1987 Google Scholar
Holsboer F. Implications of altered limbic-hypothalamicpituitary-adrenocortical (LHPA)-function for the neurobiology of depression. Acta Psychiatr Scand 1988; 341(Suppl.): 72–111 ArticleCAS Google Scholar
Sapolsky RM. A mechanism of glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults. J Neurosci 1985; 5: 1228–32 PubMedCAS Google Scholar
Sapolsky RM, Paean DR, Vale WW. Glucocorticoid toxicity in the hippocampus: in vitro demonstration. Brain Res 1988; 453: 367–71 ArticlePubMedCAS Google Scholar
Masters J, Finch C, Sapolsky R. Glucocorticoid endangerment of hippocampal neurons does not involve deoxyribonucleic acid cleavage. Endocrinology 1989; 124: 3083–8 ArticlePubMedCAS Google Scholar
Johnson M, Stone D, Bush L, et al. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. Eur J Pharmacol 1989; 161: 181–8 ArticlePubMedCAS Google Scholar
Kirkegaard C, Faber J, Hummer L, et al. Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology 1979; 4: 227–35 ArticlePubMedCAS Google Scholar
Prange AJ, Lara PP, Wilson IC, et al. Effects of thyrotropin-releasing hormone in depression. Lancet 1972; ii: 99–1002 Google Scholar
Nemeroff CB, Simon JS, Haggerty JJ, et al. Antithyroid antibodies in depressed patients. Am J Psychiatry 1985; 142: 840–3 PubMedCAS Google Scholar
Carrol BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry 1982; 140: 292–304 Article Google Scholar
Sachar EJ, Hellman L, Fukushima DK, et al. Cortisol production in depressive illness. Arch Gen Psychiatry 1970; 23: 289–98 ArticlePubMedCAS Google Scholar
Nemeroff CB, Widerlov E, Bissett G, et al. Elevated concentration of CSF corticotropin releasing factor-like immuno-reactivity in depressed patients. Science 1984; 226: 1342–4 ArticlePubMedCAS Google Scholar
Nemeroff CB, Ranga K, Krishnan RR, et al. Adrenal gland enlargement in major depression. Arch Gen Psychiatry 1992; 49: 384–7 ArticlePubMedCAS Google Scholar
Arenzana-Seisdedos F, Virelizer JL. Interferons as macrophage-activating factors: II. Enhanced secretion of interleukin-1 by lipopolysaccharide-stimulated human monocytes. Eur J Immunol 1983; 13: 437–40 ArticlePubMedCAS Google Scholar
Herman J, Kew M, Rabson A. Defective interleukin-1 production by monocytes from patients with malignant disease. Cancer Immunol Immunother 1984; 16: 182–5 ArticlePubMedCAS Google Scholar
Mier JW, Vachino G, Van Der Meer JWM, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8: 426–36 ArticlePubMedCAS Google Scholar
Breder C, Dinarello CA, Saper C. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240: 321–4 ArticlePubMedCAS Google Scholar
Farrar W, Killian P, Ruff M, et al. Visualization and characterization of interleukin-1 receptors in brain. J Immunol 1987; 139: 459–63 PubMedCAS Google Scholar
Kabiersch A, Del Rey A, Honegger CG, et al. Interleukin-1 produces changes in norepinephrine metabolism in the rat brain. Brain Behav Immun 1988; 2: 267–74 ArticlePubMedCAS Google Scholar
Plata-Salaman CR, Ffrench-Mullen JM. Interleukin-1 beta depresses calcium currents in CA1 hippocampal neurons at pathophysiological concentrations. Brain Res Bull 1992; 29: 221–3 ArticlePubMedCAS Google Scholar
Mier JW, Vachino G, Lempner MS, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990; 76: 1933–40 PubMedCAS Google Scholar
Ellison MD, Merchant RE. Appearance of cytokine-associated central nervous system myelin damage coincides temporarily with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. J Neuroimmunol 1991; 33: 245–51 ArticlePubMedCAS Google Scholar
Waage A, Espevik T. Interleukin-1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med 1988; 167: 1987–92 ArticlePubMedCAS Google Scholar
Wollman EE, Kopmels B, Bakalian A, et al. Cytokines and neuronal degeneration. In: Rothwell NJ, Dantzer RD, editors. Interleukin-1 in the brain. New York: Pergamon Press, 1992: 187–203 Google Scholar
Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology, 6th ed. New York: Oxford University Press, 1991 Google Scholar
Blalock JE, Smith EM. Human leukocyte interferon (HuIFN-α): potent endorphin-like opioid activity. Biochem Biophys Res Commun 1981; 101: 472–8 ArticlePubMedCAS Google Scholar
Birmanns B, Saphier D, Abramsky O. α-Interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone. J Neurol Sci 1990; 100: 22–6 ArticlePubMedCAS Google Scholar
Ho B, Huo Y, Lu J, et al. Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-α. Pharmacol Biochem Behav 1991; 42: 57–60 Article Google Scholar
Ho BT, Lu JG, Huo YY, et al. Neurochemical basis of interleukin-2 modified discrimination behavior. Cytokines. In press
Dafny N, Reyes-Vazquez C. Single injection of three different preparations of α-interferon modifies morphine abstinence for a prolonged period. Int J Neurosci 1987; 32: 953–61 ArticlePubMedCAS Google Scholar
Dafny N, Zielinski M, Reyes-Vazquez C. Alteration of morphine withdrawal to naloxone by interferon. Neuropeptides 1983; 3: 453–63 ArticlePubMedCAS Google Scholar
Nakashima T, Hori T, Kiriyama K. et al. Naloxone blocks the interferon-α induced changes in hypothalamic neuronal activity. Neurosci Lett 1987; 82: 332–6 ArticlePubMedCAS Google Scholar
Levine P, Silberfarb P, Kipowski Z. Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978; 43: 1385–91 Article Google Scholar
Folstein M, Folstein S, McHugh P. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98 ArticlePubMedCAS Google Scholar
Auerbach V, Faibish G. Mini-mental state examination: diagnostic limitations [abstract]. J Clin Exp Neuropsychol 1989; 11: 75 Google Scholar
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association, 1994
Smith M, Khayat D. Residual acute confusional and hallucinatory syndromes induced by interleukin-2/α-interferon treatment. Psycho-oncology 1992; 1: 115–8 Article Google Scholar
Levenson J, Fallon H. Fluoxetine treatment of depression caused by interferon-α. Am J Gastroenterol 1993; 88: 760–1 PubMedCAS Google Scholar
Goldman LS. Successful treatment of interferon-alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35: 412–3 ArticlePubMedCAS Google Scholar
Valentine A, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-a with naltrexone. Cancer Invest. In press
Fossa SD. Improved subjective tolerability of interferon by combination with prednisolone. Eur J Can Clin Oncol 1987; 23: 875–6 ArticleCAS Google Scholar
Abdi EA. Combination of interferon and prednisone in human cancer. Eur J Can Clin Oncol 1988; 24: 723–4 ArticleCAS Google Scholar
Fossa SD, Gunderson R, Moe B. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Cancer 1990; 65: 2451–4 ArticlePubMedCAS Google Scholar
Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989; 7: 479–91 ArticlePubMedCAS Google Scholar